{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T03:03:22Z","timestamp":1780023802387,"version":"3.53.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012620","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202408342"],"award-info":[{"award-number":["tsqn202408342"]}],"id":[{"id":"10.13039\/100012620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012620","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tspd20210321"],"award-info":[{"award-number":["tspd20210321"]}],"id":[{"id":"10.13039\/100012620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012620","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tstp20230653"],"award-info":[{"award-number":["tstp20230653"]}],"id":[{"id":"10.13039\/100012620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270174"],"award-info":[{"award-number":["82270174"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300189"],"award-info":[{"award-number":["82300189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470153"],"award-info":[{"award-number":["82470153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370165"],"award-info":[{"award-number":["82370165"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024MH209"],"award-info":[{"award-number":["ZR2024MH209"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2020KH016"],"award-info":[{"award-number":["ZR2020KH016"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH073"],"award-info":[{"award-number":["ZR2023QH073"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ECCM Program of Clinical Research Center of Shandong University","award":["2021SDUCRCB008"],"award-info":[{"award-number":["2021SDUCRCB008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Funct Integr Genomics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10142-026-01895-z","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T02:40:59Z","timestamp":1780022459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating ex vivo drug sensitivity and genetic mutation analysis improves prediction of chemotherapy response in acute myeloid leukemia"],"prefix":"10.1007","volume":"26","author":[{"given":"W\u011bi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruinan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qirui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"1895_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, G\u00f6kbuget N, Gotlib J, Hellstr\u00f6m-Lindberg E, Hobbs GS, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, L\u00f6wenberg B, Macintyre E, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, D\u00f6hner H, Tefferi A (2022) International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140:1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"key":"1895_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.clml.2013.11.006","volume":"14","author":"TA Bennett","year":"2014","unstructured":"Bennett TA, Montesinos P, Moscardo F, Martinez-Cuadron D, Martinez J, Sierra J, Garc\u00eda R, de Oteyza JP, Fernandez P, Serrano J, Fernandez A, Herrera P, Gonzalez A, Bethancourt C, Rodriguez-Macias G, Alonso A, Vera JA, Navas B, Lavilla E, Lopez JA, Jimenez S, Simiele A, Vidriales B, Gonzalez BJ, Burgaleta C, Hernandez Rivas JA, Mascu\u00f1ano RC, Bautista G, Perez Simon JA, Fuente Ade L, Ray\u00f3n C, Troconiz IF, Janda A, Bosanquet AG, Hernandez-Campo P, Primo D, Lopez R, Liebana B, Rojas JL, Gorrochategui J, Sanz MA, Ballesteros J (2014) Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. Clin Lymphoma Myeloma Leuk 14:305\u2013318. https:\/\/doi.org\/10.1016\/j.clml.2013.11.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1895_CR3","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","volume":"125","author":"AK Burnett","year":"2015","unstructured":"Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin MF, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE (2015) A randomized comparison of daunorubicin 90\u00a0mg\/m2 vs 60\u00a0mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125:3878\u20133885. https:\/\/doi.org\/10.1182\/blood-2015-01-623447","journal-title":"Blood"},{"key":"1895_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","volume":"17","author":"L Chen","year":"2005","unstructured":"Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DCS (2005) Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function. Mol Cell 17:393\u2013403. https:\/\/doi.org\/10.1016\/j.molcel.2004.12.030","journal-title":"Mol Cell"},{"key":"1895_CR5","doi-asserted-by":"publisher","first-page":"eabl5220","DOI":"10.1126\/sciadv.abl5220","volume":"8","author":"X Chen","year":"2022","unstructured":"Chen X, Zhou W, Song RH, Liu S, Wang S, Chen Y, Gao C, He C, Xiao J, Zhang L, Wang T, Liu P, Duan K, Cheng Z, Zhang C, Zhang J, Sun Y, Jackson F, Lan F, Liu Y, Xu Y, Wong JJ, Wang P, Yang H, Xiong Y, Chen T, Li Y, Ye D (2022) Tumor suppressor CEBPA interacts with and inhibits DNMT3A activity. Sci Adv 8:eabl5220. https:\/\/doi.org\/10.1126\/sciadv.abl5220","journal-title":"Sci Adv"},{"key":"1895_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, R\u00f6llig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, L\u00f6wenberg B (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"1895_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, D\u00f6hner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, H\u00e1jek R, Porkka K, Ill\u00e9s \u00c1, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW (2020) Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383:617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"1895_CR8","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1182\/blood.V93.8.2478","volume":"93","author":"EH Estey","year":"1999","unstructured":"Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E (1999) Randomized phase II study of fludarabine\u2009+\u2009cytosine arabinoside\u2009+\u2009idarubicin +\/- all-trans retinoic acid +\/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93:2478\u20132484","journal-title":"Blood"},{"key":"1895_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-026-01495-x","author":"S Fathima","year":"2026","unstructured":"Fathima S, Rokach L, Ghosoun N, Rezasoltani M, Ilyas R, Alsugair A, McCullough K, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar AA, Matin A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Punwani N, Sproat L, Khera N, Arana Yi C, Tefferi A, Gangat N (2026) CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients. Blood Cancer J. https:\/\/doi.org\/10.1038\/s41408-026-01495-x","journal-title":"Blood Cancer J"},{"key":"1895_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, L\u00f6wenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553\u2013567. https:\/\/doi.org\/10.1016\/j.ccr.2010.11.015","journal-title":"Cancer Cell"},{"key":"1895_CR11","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","volume":"45","author":"M Forsberg","year":"2024","unstructured":"Forsberg M, Konopleva M (2024) AML treatment: conventional chemotherapy and emerging novel agents. Trends Pharmacol Sci 45:430\u2013448. https:\/\/doi.org\/10.1016\/j.tips.2024.03.005","journal-title":"Trends Pharmacol Sci"},{"key":"1895_CR12","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41580-019-0159-6","volume":"20","author":"MVC Greenberg","year":"2019","unstructured":"Greenberg MVC, Bourc\u2019his D (2019) The diverse roles of DNA methylation in mammalian development and disease. Nat Rev Mol Cell Biol 20:590\u2013607. https:\/\/doi.org\/10.1038\/s41580-019-0159-6","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1895_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.exphem.2017.07.002","volume":"54","author":"C Hassan","year":"2017","unstructured":"Hassan C, Afshinnekoo E, Li S, Wu S, Mason CE (2017) Genetic and epigenetic heterogeneity and the impact on cancer relapse. Exp Hematol 54:26\u201330. https:\/\/doi.org\/10.1016\/j.exphem.2017.07.002","journal-title":"Exp Hematol"},{"key":"1895_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1177\/2472630317700346","volume":"22","author":"P Hern\u00e1ndez","year":"2017","unstructured":"Hern\u00e1ndez P, Gorrochategui J, Primo D, Robles A, Rojas JL, Espinosa AB, G\u00f3mez C, Mart\u00ednez-L\u00f3pez J, Bennett TA, Ballesteros J (2017) Drug Discovery Testing Compounds in Patient Samples by Automated Flow Cytometry. SLAS Technol 22:325\u2013337. https:\/\/doi.org\/10.1177\/2472630317700346","journal-title":"SLAS Technol"},{"key":"1895_CR15","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1200\/jco.2011.37.1286","volume":"30","author":"J Holowiecki","year":"2012","unstructured":"Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, Skotnicki AB, Hellmann A, Sulek K, Dmoszynska A, Kloczko J, Jedrzejczak WW, Zdziarska B, Warzocha K, Zawilska K, Komarnicki M, Kielbinski M, Piatkowska-Jakubas B, Wierzbowska A, Wach M, Haus O (2012) Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 30:2441\u20132448. https:\/\/doi.org\/10.1200\/jco.2011.37.1286","journal-title":"J Clin Oncol"},{"key":"1895_CR16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/sj.leu.2403336","volume":"18","author":"J Holowiecki","year":"2004","unstructured":"Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, Skotnicki A, Jedrzejczak WW, Konopka L, Kuliczkowski K, Zdziarska B, Dmoszynska A, Marianska B, Pluta A, Zawilska K, Komarnicki M, Kloczko J, Sulek K, Haus O, Stella-Holowiecka B, Baran W, Jakubas B, Paluszewska M, Wierzbowska A, Kielbinski M, Jagoda K (2004) Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 18:989\u2013997. https:\/\/doi.org\/10.1038\/sj.leu.2403336","journal-title":"Leukemia"},{"key":"1895_CR17","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","volume":"33","author":"BA Jonas","year":"2019","unstructured":"Jonas BA, Pollyea DA (2019) How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia 33:2795\u20132804. https:\/\/doi.org\/10.1038\/s41375-019-0612-8","journal-title":"Leukemia"},{"key":"1895_CR18","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/ajh.27054","volume":"98","author":"TM Kadia","year":"2023","unstructured":"Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian H (2023) Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol 98:1711\u20131720. https:\/\/doi.org\/10.1002\/ajh.27054","journal-title":"Am J Hematol"},{"key":"1895_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, Jabbour E, Schiffer CA, Lang A, Ravandi F (2025) Acute myeloid leukemia management and research in 2025. CA Cancer J Clin 75:46\u201367. https:\/\/doi.org\/10.3322\/caac.21873","journal-title":"CA Cancer J Clin"},{"key":"1895_CR20","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","volume":"2","author":"A Khwaja","year":"2016","unstructured":"Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen JJ, Scheinberg DA, Bouscary D, Linch DC (2016) Acute myeloid leukaemia. Nat Rev Dis Primers 2:16010. https:\/\/doi.org\/10.1038\/nrdp.2016.10","journal-title":"Nat Rev Dis Primers"},{"key":"1895_CR21","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1126\/science.275.5303.1132","volume":"275","author":"RM Kluck","year":"1997","unstructured":"Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD (1997) The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis. Science 275:1132\u20131136. https:\/\/doi.org\/10.1126\/science.275.5303.1132","journal-title":"Science"},{"key":"1895_CR22","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR, Fulton RS, Dooling DJ, Koboldt DC, Schmidt H, Zhang Q, Osborne JR, Lin L, O\u2019Laughlin M, McMichael JF, Delehaunty KD, McGrath SD, Fulton LA, Magrini VJ, Vickery TL, Hundal J, Cook LL, Conyers JJ, Swift GW, Reed JP, Alldredge PA, Wylie T, Walker J, Kalicki J, Watson MA, Heath S, Shannon WD, Varghese N, Nagarajan R, Westervelt P, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Wilson RK (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:2424\u20132433. https:\/\/doi.org\/10.1056\/NEJMoa1005143","journal-title":"N Engl J Med"},{"key":"1895_CR23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/jlb.5a0220-676rr","volume":"107","author":"L Lin","year":"2020","unstructured":"Lin L, Tong Y, Straube J, Zhao J, Gao Y, Bai P, Li J, Wang J, Wang H, Wang X, Huang S, Xu W, Song X, Li L (2020) Ex-vivo drug testing predicts chemosensitivity in acute myeloid leukemia. J Leukoc Biol 107:859\u2013870. https:\/\/doi.org\/10.1002\/jlb.5a0220-676rr","journal-title":"J Leukoc Biol"},{"key":"1895_CR24","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","volume":"361","author":"B L\u00f6wenberg","year":"2009","unstructured":"L\u00f6wenberg B, Ossenkoppele GJ, Putten Wv, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, Lilienfeld-Toal Mv, Biemond BJ, Vellenga E, Kooy MM, Verdonck LF, Beck J, D\u00f6hner H, Gratwohl A, Pabst T, Verhoef G (2009) High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia. N Engl J Med 361:1235\u20131248. https:\/\/doi.org\/10.1056\/NEJMoa0901409","journal-title":"N Engl J Med"},{"key":"1895_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2018.11.006","volume":"76","author":"D Mart\u00ednez-Cuadr\u00f3n","year":"2019","unstructured":"Mart\u00ednez-Cuadr\u00f3n D, Gil C, Serrano J, Rodr\u00edguez G, P\u00e9rez-Oteyza J, Garc\u00eda-Boyero R, Jim\u00e9nez-Bravo S, Vives S, Vidriales MB, Lavilla E, P\u00e9rez-Sim\u00f3n JA, Tormo M, Colorado M, Bergua J, L\u00f3pez JA, Herrera P, Hern\u00e1ndez-Campo P, Gorrochategui J, Primo D, Rojas JL, Villoria J, Moscard\u00f3 F, Troconiz I, Linares G\u00f3mez M, Mart\u00ednez-L\u00f3pez J, Ballesteros J, Sanz M, Montesinos P (2019) A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. Leuk Res 76:1\u201310. https:\/\/doi.org\/10.1016\/j.leukres.2018.11.006","journal-title":"Leuk Res"},{"key":"1895_CR26","doi-asserted-by":"publisher","first-page":"e2019016","DOI":"10.4084\/mjhid.2019.016","volume":"11","author":"JE Meg\u00edas-Vericat","year":"2019","unstructured":"Meg\u00edas-Vericat JE, Mart\u00ednez-Cuadr\u00f3n D, L\u00f3pez JM, Bergua JM, Tormo M, Serrano J, Gonz\u00e1lez A, de Oteyza JP, Vives S, Vidriales B, Herrera P, Vera JA, Mart\u00ednez AL, de la Fuente A, Amador ML, Hern\u00e1ndez-Rivas J, Fern\u00e1ndez M, Cerver\u00f3 CJ, Morillo D, Campo PH, Gorrochategui J, Primo D, Rojas JL, Guenova M, Ballesteros J, Sanz M, Montesinos P (2019) Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia. Mediterr J Hematol Infect Dis 11:e2019016. https:\/\/doi.org\/10.4084\/mjhid.2019.016","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"1895_CR27","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/ajh.23544","volume":"88","author":"A Nazha","year":"2013","unstructured":"Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S (2013) Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients\u2009\u2264\u200960 years with newly diagnosed acute myeloid leukemia. Am J Hematol 88:961\u2013966. https:\/\/doi.org\/10.1002\/ajh.23544","journal-title":"Am J Hematol"},{"key":"1895_CR28","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/bjh.16432","volume":"189","author":"E Onecha","year":"2020","unstructured":"Onecha E, Ruiz-Heredia Y, Mart\u00ednez-Cuadr\u00f3n D, Barrag\u00e1n E, Martinez-Sanchez P, Linares M, Rapado I, Perez-Oteyza J, Magro E, Herrera P, Rojas JL, Gorrochategui J, Villoria J, Boluda B, Sargas C, Ballesteros J, Montesinos P, Mart\u00ednez-L\u00f3pez J, Ayala R (2020) Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity. Br J Haematol 189:672\u2013683. https:\/\/doi.org\/10.1111\/bjh.16432","journal-title":"Br J Haematol"},{"key":"1895_CR29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.Cd-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, D\u00f6hner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, M\u00fcschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG (2014) Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 4:362\u2013375. https:\/\/doi.org\/10.1158\/2159-8290.Cd-13-0609","journal-title":"Cancer Discov"},{"key":"1895_CR30","doi-asserted-by":"publisher","first-page":"119047","DOI":"10.1016\/j.bbamcr.2021.119047","volume":"1868","author":"G Prado","year":"2021","unstructured":"Prado G, Kaestner CL, Licht JD, Bennett RL (2021) Targeting epigenetic mechanisms to overcome venetoclax resistance. Biochim Biophys Acta Mol Cell Res 1868:119047. https:\/\/doi.org\/10.1016\/j.bbamcr.2021.119047","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"1895_CR31","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1200\/jco.21.01546","volume":"40","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, Garcia JS, DiNardo CD, Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, Chyla B, Potluri J, D\u00f6hner H (2022) Measurable Residual Disease Response and Prognosis in Treatment-Na\u00efve Acute Myeloid Leukemia With Venetoclax and Azacitidine. J Clin Oncol 40:855\u2013865. https:\/\/doi.org\/10.1200\/jco.21.01546","journal-title":"J Clin Oncol"},{"key":"1895_CR32","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ccr.2014.02.010","volume":"25","author":"DA Russler-Germain","year":"2014","unstructured":"Russler-Germain DA, Spencer DH, Young MA, Lamprecht TL, Miller CA, Fulton R, Meyer MR, Erdmann-Gilmore P, Townsend RR, Wilson RK, Ley TJ (2014) The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25:442\u2013454. https:\/\/doi.org\/10.1016\/j.ccr.2014.02.010","journal-title":"Cancer Cell"},{"key":"1895_CR33","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/s0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE (2018) Acute myeloid leukaemia. Lancet 392:593\u2013606. https:\/\/doi.org\/10.1016\/s0140-6736(18)31041-9","journal-title":"Lancet"},{"key":"1895_CR34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202\u2013208. https:\/\/doi.org\/10.1038\/nm.3048","journal-title":"Nat Med"},{"key":"1895_CR35","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1038\/bcj.2015.114","volume":"6","author":"F St\u00f6lzel","year":"2016","unstructured":"St\u00f6lzel F, Mohr B, Kramer M, Oelschl\u00e4gel U, Bochtler T, Berdel WE, Kaufmann M, Baldus CD, Sch\u00e4fer-Eckart K, Stuhlmann R, Einsele H, Krause SW, Serve H, H\u00e4nel M, Herbst R, Neubauer A, Sohlbach K, Mayer J, Middeke JM, Platzbecker U, Schaich M, Kr\u00e4mer A, R\u00f6llig C, Schetelig J, Bornh\u00e4user M, Ehninger G (2016) Karyotype complexity and prognosis in acute myeloid leukemia. Blood Cancer J 6:e386. https:\/\/doi.org\/10.1038\/bcj.2015.114","journal-title":"Blood Cancer J"},{"key":"1895_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1182\/blood.2020009680","volume":"139","author":"F Taube","year":"2022","unstructured":"Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, R\u00f6llig C, Krug U, Kr\u00e4mer A, Scholl S, Hochhaus A, Br\u00fcmmendorf TH, Naumann R, Petzold A, Mulet-Lazaro R, Valk PJM, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Sch\u00e4fer-Eckart K, Schliemann C, Krause SW, H\u00e4nel M, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Herold S, St\u00f6lzel F, Sockel K, von Bonin M, M\u00fcller-Tidow C, Platzbecker U, Berdel WE, Serve H, Ehninger G, Bornh\u00e4user M, Schetelig J, Thiede C (2022) CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood 139:87\u2013103. https:\/\/doi.org\/10.1182\/blood.2020009680","journal-title":"Blood"},{"key":"1895_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/bloodadvances.2021004292","volume":"6","author":"S Wakita","year":"2022","unstructured":"Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Tajika K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Kayamori K, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Kurosawa A, Mizoguchi A, Komatsu N, Fukuda T, Ohashi K, Kanda Y, Inokuchi K, Yamaguchi H (2022) Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Adv 6:238\u2013247. https:\/\/doi.org\/10.1182\/bloodadvances.2021004292","journal-title":"Blood Adv"},{"key":"1895_CR38","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/s2352-3026(22)00106-5","volume":"9","author":"H Wang","year":"2022","unstructured":"Wang H, Mao L, Yang M, Qian P, Lu H, Tong H, Xie W, Zhou D, Huang X, Wang Y, Xu G, Lu Y, Wei J, Mai W, Ye X, Meng H, Shen Y, Huang J, Yu W, Sun J, Sheng J, Yan X, Jin J, Zhu HH (2022) Venetoclax plus 3\u2009+\u20097 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol 9:e415\u2013e424. https:\/\/doi.org\/10.1016\/s2352-3026(22)00106-5","journal-title":"Lancet Haematol"},{"key":"1895_CR39","doi-asserted-by":"publisher","first-page":"e3260","DOI":"10.1002\/hon.3260","volume":"42","author":"R Wang","year":"2024","unstructured":"Wang R, Zhang Y, Chang J, Wang H, Lou Y, Yang M, Xu G, Tong H, Xie W, Zhou D, Wei J, Mai W, Ye X, Meng H, Jin J, Zhu HH (2024) Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score-matched analysis. Hematol Oncol 42:e3260. https:\/\/doi.org\/10.1002\/hon.3260","journal-title":"Hematol Oncol"},{"key":"1895_CR40","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00277-020-03911-z","volume":"99","author":"Y-W Wang","year":"2020","unstructured":"Wang Y-W, Tsai C-H, Lin C-C, Tien F-M, Chen Y-W, Lin H-Y, Yao M, Lin Y-C, Lin C-T, Cheng C-L, Tang J-L, Chou W-C, Hou H-A, Tien H-F (2020) Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Ann Hematol 99:501\u2013511. https:\/\/doi.org\/10.1007\/s00277-020-03911-z","journal-title":"Ann Hematol"},{"key":"1895_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","volume":"19","author":"W Xu","year":"2011","unstructured":"Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17\u201330. https:\/\/doi.org\/10.1016\/j.ccr.2010.12.014","journal-title":"Cancer Cell"},{"key":"1895_CR42","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.275.5303.1129","volume":"275","author":"J Yang","year":"1997","unstructured":"Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng T-I, Jones DP, Wang X (1997) Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked. Science 275:1129\u20131132. https:\/\/doi.org\/10.1126\/science.275.5303.1129","journal-title":"Science"},{"key":"1895_CR43","doi-asserted-by":"publisher","unstructured":"Yang X, Wong MPM, Ng RK (2019) Aberrant DNA methylation in acute myeloid leukemia and its clinical implications. Int J Mol Sci 20. https:\/\/doi.org\/10.3390\/ijms20184576","DOI":"10.3390\/ijms20184576"},{"key":"1895_CR44","first-page":"485","volume":"1 57","author":"JW Yates","year":"1973","unstructured":"Yates JW, Wallace HJ, Ellison RR, Holland JF (1973) CYTOSINE-ARABINOSIDE (NSC-63878) AND DAUNORUBICIN (NSC-83142) THERAPY IN ACUTE NONLYMPHOCYTIC LEUKEMIA. Cancer Chemother Rep Part 1 57:485\u2013488","journal-title":"Cancer Chemother Rep Part"},{"key":"1895_CR45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1158\/1078-0432.CCR-24-1332","volume":"31","author":"G Yu","year":"2025","unstructured":"Yu G, Zhang Y, Yu S, Yin Z, Weng G, Xu N, Du X, Lin D, Xiao J, Sun Z, Zhang H, Liang X, Guo Z, Zhao W, Dai M, Fan Z, Xuan L, Liu H, Xu D, Ye J, Jiang X, Shi P, Jin H, Liu Q (2025) Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed\/Refractory AML: A Multicenter Cohort Study. Clin Cancer Res 31:87\u201397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1332","journal-title":"Clin Cancer Res"},{"key":"1895_CR46","doi-asserted-by":"publisher","first-page":"793773","DOI":"10.3389\/fonc.2021.793773","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Ji M, Zhao JY, Wang HF, Wang CW, Li W, Ye JJ, Lu F, Lin LH, Gao YT, Jin J, Li L, Ji CY, Ballesteros J, Zhu HH (2021) Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy. Front Oncol 11:793773. https:\/\/doi.org\/10.3389\/fonc.2021.793773","journal-title":"Front Oncol"}],"container-title":["Functional &amp; Integrative Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-026-01895-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10142-026-01895-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-026-01895-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T02:41:01Z","timestamp":1780022461000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10142-026-01895-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1895"],"URL":"https:\/\/doi.org\/10.1007\/s10142-026-01895-z","relation":{},"ISSN":["1438-793X","1438-7948"],"issn-type":[{"value":"1438-793X","type":"print"},{"value":"1438-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Research Ethics Committee of Qilu Hospital with the reference number KYLL-2020(KS)-633.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}